The limits of limited stage lymphoma

Journal of Clinical Oncology

Volumn 22, Issue 15, 2004, Pages 2982-2984

  Miller, Thomas P ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; PREDNISOLONE; VAP CYCLO PROTOCOL; VAP-CYCLO PROTOCOL;

ADVANCED CANCER; CANCER GROWTH; CANCER MORTALITY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; DRUG EFFICACY; EDITORIAL; HUMAN; LOW ENERGY RADIATION; LYMPHOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; NOTE; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; HUMANS; LYMPHOMA, NON-HODGKIN; PREDNISOLONE; RADIOTHERAPY DOSAGE; RANDOMIZED CONTROLLED TRIALS; VINCRISTINE;

EID: 4143114747     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.05.926     Document Type: Editorial

References (9)

1. Horning SJ, Weller E, KyungMann K, et al: Chemotherapy with or without radiotherapy in limited stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol 22:3032-3038, 2004
2. Miller TP, Dahlberg S, Cassady JR, et al: Chemotherapy alone compared to chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med 339:21-26, 1998
3. Reyes F, Lepage E, Munck JN, et al: Superiority of chemotherapy alone with the ACVBP regimen over treatment with three cycles of CHOP plus radiotherapy in low risk localized aggressive lymphoma: The LNH93-1 GELA study. Blood 100:93a, 2002 (abstr 343)
4. Shenkier TN, Voss N, Fairey R, et al: Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma: An 18-year experience from the British Columbia Cancer Agency. J Clin Oncol 20:197-204, 2002
5. A predictive model for aggressive non-Hodgkin's lymphoma: The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329:987-994, 1993
6. Fisher RI, DeVita VT, Johnson BL, et al: Prognostic factors for advanced diffuse histiocytic lymphoma following treatment with combination chemotherapy: Am J Med 63:177-182, 1977
7. Miller TP, LeBlanc M, Spier C, et al: CHOP alone compared to CHOP plus radiotherapy for early stage aggressive non-Hodgkin's lymphomas: Update of the Southwest Oncology Group (SWOG) randomized trial. Blood 98:724a-725a, 2001 (abstr 3024)
8. Coiffier B, Lepage E, Briere J, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 346:235-242, 2002
9. Sehn LH, Donaldson J, Chhanabhai M, et al: Introduction of combined CHOP-rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma (DLBC) in British Columbia (BC). Blood 102:29a, 2003 (abstr 3024)